Topics
ArticleThe future of academic core labs: scaling operational excellence without increasing staff
The grounds have shifted the foundations of academic core facilities and the current climate demands their strategic agility in order to thrive. Boyd Butler at Molecular Devices reveals how these labs can capitalise on this opportunity to increase value and efficiency.
ArticleAnalytica 2026: Connecting data across drug discovery workflows
Drug discovery is generating more data than ever, but the challenge is making sure that data is reliable, connected and usable. At Analytica 2026 in Munich, Drug Target Review spoke with technology developers and industry leaders across the exhibition floor to understand how these challenges are being addressed.
ArticleAI builds dual-action cancer drug targeting PKMYT1
Research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both eliminates the target protein and blocks its activity, demonstrating the growing role of AI in advanced drug discovery.
ArticleAI to antibody in days: breaking the wet lab bottleneck via high-throughput integration
AI is accelerating drug discovery at an unprecedented pace. Thousands of antibody candidates can now be designed in silico within hours. The challenge now is keeping experimental workflows fast enough to keep up. High-throughput expression and integrated developability assessment are making it possible to move from sequence to data in days.
WebinarWhat it takes to automate high-content imaging at scale
This webinar examines the design trade-offs and technical constraints involved in building a high-throughput robotic imaging pipeline for complex biological workflows.
WebinarThe truth about AI in drug discovery: what the experts really think
AI in drug discovery is evolving fast. Join the experts behind today’s real progress as they share what works, what doesn’t and what you need to know next.
WebinarCan One Peptide Change Pain Research? Meet the Tool Transforming Drug Discovery
Discover how a new peptide tool, WRPRFa, is helping researchers better understand pain pathways and accelerate the search for next-generation analgesics.
WebinarOvercoming Affinity and Expression Bottlenecks in TCR Discovery
This expert-led webinar discusses how to break through common bottlenecks in TCR discovery with practical strategies that help teams move faster and smarter.
NewsNasal spray reverses age-related brain inflammation in preclinical study
Researchers at Texas A&M University have developed a nasal spray delivering extracellular vesicles that reverses neuroinflammaging in preclinical models. Two doses significantly reduced brain inflammation, restored mitochondrial function and improved memory within weeks, with effects persisting for months. The therapy bypasses the blood-brain barrier and targets inflammatory pathways whilst reactivating cellular energy production.
NewsCircio and Acuitas partner on circular RNA CAR T therapy
Norway-based biotechnology company Circio Holding ASA has partnered with Acuitas Therapeutics to evaluate its circVec circular RNA platform for in vivo CAR T cell therapy. The collaboration will combine Circio’s technology, which reportedly delivers gene expression lasting up to six months in lymphocytes, with Acuitas’ lipid nanoparticle delivery system targeting specific T cell populations for potential applications in oncology and autoimmune diseases.
ArticleBeyond serendipity: rational design and AI’s expansion of the undruggable target landscape
For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.
NewsOsteoporosis drugs may slow progression of aortic aneurysms
Researchers at Nagoya University have identified clonal haematopoiesis as a driver of aortic aneurysm progression and demonstrated that FDA-approved osteoporosis therapies targeting the RANK/RANKL pathway can significantly slow disease progression in preclinical models.
- Article
Analytica 2026: Connecting data across drug discovery workflows
Drug discovery is generating more data than ever, but the challenge is making sure that data is reliable, connected and usable. At Analytica 2026 in Munich, Drug Target Review spoke with technology developers and industry leaders across the exhibition floor to understand how these challenges are being addressed.
- Article
AI builds dual-action cancer drug targeting PKMYT1
Research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both eliminates the target protein and blocks its activity, demonstrating the growing role of AI in advanced drug discovery.
- Article
AI to antibody in days: breaking the wet lab bottleneck via high-throughput integration
AI is accelerating drug discovery at an unprecedented pace. Thousands of antibody candidates can now be designed in silico within hours. The challenge now is keeping experimental workflows fast enough to keep up. High-throughput expression and integrated developability assessment are making it possible to move from sequence to data in days.
ArticleImproving selectivity in antibody–drug conjugates
Promatix Biosciences is developing a new generation of bispecific antibody–drug conjugates using proprietary membrane proteomics data to identify highly selective target pairings. CEO Dr Michael Hunter explains how the company’s TXPro database enables discovery of previously unexplored tumour biology to improve therapeutic index and reduce on-target/off-tumour toxicities in solid tumours.
- Article
AI builds dual-action cancer drug targeting PKMYT1
Research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both eliminates the target protein and blocks its activity, demonstrating the growing role of AI in advanced drug discovery.
- Article
AI to antibody in days: breaking the wet lab bottleneck via high-throughput integration
AI is accelerating drug discovery at an unprecedented pace. Thousands of antibody candidates can now be designed in silico within hours. The challenge now is keeping experimental workflows fast enough to keep up. High-throughput expression and integrated developability assessment are making it possible to move from sequence to data in days.
- Article
Improving selectivity in antibody–drug conjugates
Promatix Biosciences is developing a new generation of bispecific antibody–drug conjugates using proprietary membrane proteomics data to identify highly selective target pairings. CEO Dr Michael Hunter explains how the company’s TXPro database enables discovery of previously unexplored tumour biology to improve therapeutic index and reduce on-target/off-tumour toxicities in solid tumours.
NewsOvarian follicles provide new platform for angiogenesis research
A novel microphysiological system using ovarian follicles enables physiologically relevant three-dimensional angiogenesis modelling within 24 hours, offering improved drug screening capabilities that distinguish therapeutic effects from general toxicity.
- Article
Analytica 2026: Connecting data across drug discovery workflows
Drug discovery is generating more data than ever, but the challenge is making sure that data is reliable, connected and usable. At Analytica 2026 in Munich, Drug Target Review spoke with technology developers and industry leaders across the exhibition floor to understand how these challenges are being addressed.
- Article
AI builds dual-action cancer drug targeting PKMYT1
Research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both eliminates the target protein and blocks its activity, demonstrating the growing role of AI in advanced drug discovery.
- Article
Improving selectivity in antibody–drug conjugates
Promatix Biosciences is developing a new generation of bispecific antibody–drug conjugates using proprietary membrane proteomics data to identify highly selective target pairings. CEO Dr Michael Hunter explains how the company’s TXPro database enables discovery of previously unexplored tumour biology to improve therapeutic index and reduce on-target/off-tumour toxicities in solid tumours.
- News
Ovarian follicles provide new platform for angiogenesis research
A novel microphysiological system using ovarian follicles enables physiologically relevant three-dimensional angiogenesis modelling within 24 hours, offering improved drug screening capabilities that distinguish therapeutic effects from general toxicity.
NewsEli Lilly acquires CrossBridge Bio’s dual-payload ADC platform
Eli Lilly has acquired CrossBridge Bio, advancing a dual-payload antibody-drug conjugate platform developed at UTHealth Houston. The technology aims to deliver chemotherapy more precisely to tumour cells whilst minimising damage to healthy tissue, with lead candidate CBB-120 now positioned for accelerated clinical development.
- Article
Beyond serendipity: rational design and AI’s expansion of the undruggable target landscape
For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.
NewsELRIG launches inaugural US drug discovery conference 2026 in Cambridge, MA
ELRIG has announced Drug Discovery USA 2026, a free two-day conference at Pfizer Cambridge bringing together international researchers to address challenging therapeutic targets through advances in multifunctional small molecules and novel biologics.
NewsOntario invests $3.1M in next-generation cancer therapeutics
The Ontario Institute for Cancer Research has awarded $3.1 million to four provincial research teams developing novel cancer therapies designed to overcome drug resistance and reduce treatment-related toxicity.